GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group AS (OCSE:PEG) » Definitions » EV-to-FCF

Pharma Equity Group AS (OCSE:PEG) EV-to-FCF : -13.19 (As of Dec. 15, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group AS EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pharma Equity Group AS's Enterprise Value is kr269.87 Mil. Pharma Equity Group AS's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was kr-20.45 Mil. Therefore, Pharma Equity Group AS's EV-to-FCF for today is -13.19.

The historical rank and industry rank for Pharma Equity Group AS's EV-to-FCF or its related term are showing as below:

OCSE:PEG' s EV-to-FCF Range Over the Past 10 Years
Min: -16.84   Med: 8.6   Max: 9.24
Current: -13.19

During the past 13 years, the highest EV-to-FCF of Pharma Equity Group AS was 9.24. The lowest was -16.84. And the median was 8.60.

OCSE:PEG's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 8.19 vs OCSE:PEG: -13.19

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-15), Pharma Equity Group AS's stock price is kr0.18. Pharma Equity Group AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was kr-0.040. Therefore, Pharma Equity Group AS's PE Ratio (TTM) for today is At Loss.


Pharma Equity Group AS EV-to-FCF Historical Data

The historical data trend for Pharma Equity Group AS's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group AS EV-to-FCF Chart

Pharma Equity Group AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -218.57 -4.04 -19.06 -13.82 -27.90

Pharma Equity Group AS Quarterly Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.40 -27.90 -19.66 -18.65 -14.05

Competitive Comparison of Pharma Equity Group AS's EV-to-FCF

For the Biotechnology subindustry, Pharma Equity Group AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group AS's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group AS's EV-to-FCF falls into.



Pharma Equity Group AS EV-to-FCF Calculation

Pharma Equity Group AS's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=269.874/-20.453
=-13.19

Pharma Equity Group AS's current Enterprise Value is kr269.87 Mil.
Pharma Equity Group AS's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-20.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharma Equity Group AS  (OCSE:PEG) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Pharma Equity Group AS's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.18/-0.040
=At Loss

Pharma Equity Group AS's share price for today is kr0.18.
Pharma Equity Group AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.040.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Pharma Equity Group AS EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group AS's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group AS Business Description

Traded in Other Exchanges
N/A
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .